DAVID GUY KIRSCH

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma
    Suzy Kim
    Department of Radiation Oncology, Duke University Medical Center, Box 91006, Durham, NC 27710, USA
    Sarcoma 2012:680708. 2012
  2. pmc Intraoperative detection and removal of microscopic residual sarcoma using wide-field imaging
    Jeffrey K Mito
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27708, USA
    Cancer 118:5320-30. 2012
  3. pmc Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma
    Jeffrey K Mito
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 4:e8075. 2009
  4. pmc Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice
    Chang Lung Lee
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Box 91006, Durham, NC 27708, USA
    Dis Model Mech 5:397-402. 2012
  5. pmc NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition
    Rebecca D Dodd
    Corresponding Author David G Kirsch, Duke University Medical Center, Box 91006, Durham, NC 27708
    Mol Cancer Ther 12:1906-17. 2013
  6. pmc Using genetically engineered mice for radiation research
    David G Kirsch
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Radiat Res 176:275-9. 2011
  7. pmc Imaging primary lung cancers in mice to study radiation biology
    David G Kirsch
    The David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
    Int J Radiat Oncol Biol Phys 76:973-7. 2010
  8. pmc p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis
    David G Kirsch
    David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Science 327:593-6. 2010
  9. pmc Dicer1 functions as a haploinsufficient tumor suppressor
    Madhu S Kumar
    Massachusetts Institute of Technology Koch Institute for Integrative Cancer Research, Cambridge, Massachusetts 02139, USA
    Genes Dev 23:2700-4. 2009
  10. ncbi request reprint A spatially and temporally restricted mouse model of soft tissue sarcoma
    David G Kirsch
    Center for Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA
    Nat Med 13:992-7. 2007

Collaborators

  • William C Eward
  • Richard F Riedel
  • Sayan Mukherjee
  • Guy Lahat
  • Kyle C Cuneo
  • Sam S Yoon
  • Dina Lev
  • Jeffrey K Mito
  • Rebecca D Dodd
  • Yan Ma
  • Chang Lung Lee
  • Tyler Jacks
  • Yongbaek Kim
  • Suzy Kim
  • Leslie Dodd
  • Brian E Brigman
  • Madhu S Kumar
  • Alice T Shaw
  • Mohit Sachdeva
  • Jordi Barretina
  • Rhea Chitalia
  • Rafaela C Rodrigues
  • Yifan Li
  • Xiaofang Huang
  • Loretta Z Woodlief
  • W David Lee
  • Moungi G Bawendi
  • Linda G Griffith
  • Shalini Ramasunder
  • Lisa F Marshall
  • Jorge M Ferrer
  • Jessica E Carter
  • Everett J Moding
  • Alexander J Lazar
  • Jun Lu
  • Cindy Y Chen
  • Keara Lane
  • Francis J Hornicek
  • Christine Chin
  • Todd R Golub
  • Ryan E Pester
  • Lars Stangenberg

Detail Information

Publications11

  1. pmc Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma
    Suzy Kim
    Department of Radiation Oncology, Duke University Medical Center, Box 91006, Durham, NC 27710, USA
    Sarcoma 2012:680708. 2012
    ..1%. Combining BEZ235 with doxorubicin (n = 10) increased the complete response rate to 50% (P = 0.035). These studies demonstrate that PI3K pathway inhibition is a viable and attractive target for soft-tissue sarcomas...
  2. pmc Intraoperative detection and removal of microscopic residual sarcoma using wide-field imaging
    Jeffrey K Mito
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27708, USA
    Cancer 118:5320-30. 2012
    ..To help identify these patients, the authors developed an in vivo imaging system to investigate the suitability of molecular imaging for intraoperative visualization...
  3. pmc Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma
    Jeffrey K Mito
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 4:e8075. 2009
    ..These results suggest that genomic alterations present in human MFH are conserved in the LSL-Kras(G12D); p53(Flox/Flox) mouse model of soft tissue sarcoma and demonstrate the utility of this pre-clinical model...
  4. pmc Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice
    Chang Lung Lee
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Box 91006, Durham, NC 27708, USA
    Dis Model Mech 5:397-402. 2012
    ..p53(FRT) mice will enable dual recombinase technology to study cancer biology because Cre is available to modify genes specifically in stromal cells to investigate their role in tumor development, progression and response to therapy...
  5. pmc NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition
    Rebecca D Dodd
    Corresponding Author David G Kirsch, Duke University Medical Center, Box 91006, Durham, NC 27708
    Mol Cancer Ther 12:1906-17. 2013
    ..These studies suggest that MEK inhibitors should be further explored as potential sarcoma therapies in patients with tumors containing NF1 deletion...
  6. pmc Using genetically engineered mice for radiation research
    David G Kirsch
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Radiat Res 176:275-9. 2011
    ..These advances in genetic engineering provide a powerful model system to dissect both the mechanisms of normal tissue injury after irradiation and the mechanisms by which radiation cures cancer...
  7. pmc Imaging primary lung cancers in mice to study radiation biology
    David G Kirsch
    The David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
    Int J Radiat Oncol Biol Phys 76:973-7. 2010
    ..To image a genetically engineered mouse model of non-small-cell lung cancer with micro-computed tomography (micro-CT) to measure tumor response to radiation therapy...
  8. pmc p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis
    David G Kirsch
    David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Science 327:593-6. 2010
    ..These results suggest that the GI syndrome is caused by the death of GI epithelial cells and that these epithelial cells die by a mechanism that is regulated by p53 but independent of apoptosis...
  9. pmc Dicer1 functions as a haploinsufficient tumor suppressor
    Madhu S Kumar
    Massachusetts Institute of Technology Koch Institute for Integrative Cancer Research, Cambridge, Massachusetts 02139, USA
    Genes Dev 23:2700-4. 2009
    ..These findings suggest Dicer1 may be an important haploinsufficient tumor suppressor gene and, furthermore, that other factors controlling miRNA biogenesis may also function in this manner...
  10. ncbi request reprint A spatially and temporally restricted mouse model of soft tissue sarcoma
    David G Kirsch
    Center for Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA
    Nat Med 13:992-7. 2007
    ..Therefore, the intrinsic pathway of apoptosis seems sufficient to mediate p53 tumor suppression in an epithelial cancer, but not in this model of soft tissue sarcoma...
  11. ncbi request reprint Future of early detection of lung cancer: the role of mouse models
    Alice T Shaw
    Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA
    Clin Cancer Res 11:4999s-5003s. 2005
    ..The application of innovative technologies to accurate mouse models promises to accelerate the discovery of new molecular targets and imaging biomarkers for the early detection of lung cancer...

Research Grants8

  1. Mechanisms of Late Effects of Exposure to Radiation
    David Kirsch; Fiscal Year: 2009
    ..These in vivo studies will provide a mechanistic foundation for the design of safe and effective countermeasures against radiation that do not inadvertently increase late effects of radiation. ..
  2. Dissecting Mechanisms of Metastasis Through Comparative Systems Genetics
    David Kirsch; Fiscal Year: 2009
    ..Moreover, new insights into mechanisms of lung metastasis may identify novel molecular targets for sarcoma therapy. ..
  3. Mechanisms of Late Effects of Exposure to Radiation
    DAVID GUY KIRSCH; Fiscal Year: 2010
    ..These in vivo studies will provide a mechanistic foundation for the design of safe and effective countermeasures against radiation that do not inadvertently increase late effects of radiation. ..
  4. Dissecting Mechanisms of Metastasis Through Comparative Systems Genetics
    DAVID GUY KIRSCH; Fiscal Year: 2010
    ..Moreover, new insights into mechanisms of lung metastasis may identify novel molecular targets for sarcoma therapy. ..
  5. Mechanisms of Late Effects of Exposure to Radiation
    DAVID GUY KIRSCH; Fiscal Year: 2010
    ..These in vivo studies will provide a mechanistic foundation for the design of safe and effective countermeasures against radiation that do not inadvertently increase late effects of radiation. ..